Predictors and patterns of weight gain during treatment for tuberculosis in the United States of America  by Phan, Mimi N. et al.
International Journal of Infectious Diseases 53 (2016) 1–5Predictors and patterns of weight gain during treatment for
tuberculosis in the United States of America
Mimi N. Phan a, Elizabeth S. Guy a, Ruby N. Nickson a, Christina C. Kao a,b,*
a Section of Pulmonary, Critical Care, and Sleep, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
bUSDA/ARS Children’s Nutrition Research Center, Baylor College of Medicine, 1100 Bates Street, Room 7022, Houston, TX 77030, USA
A R T I C L E I N F O
Article history:
Received 23 June 2016
Received in revised form 4 September 2016
Accepted 5 September 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark.
Keywords:
Malnutrition
Underweight
Relapse
S U M M A R Y
Objectives: Patients with tuberculosis (TB) often present with weight loss. Lack of weight gain with TB
treatment has been associated with treatment failure. The purpose of this study was to examine patterns
of weight gain in patients with TB and determine the disease characteristics that predict weight gain.
Methods: This was a retrospective cohort study of adults with TB treated in a county health system in the
USA. Demographic, clinical, radiographic, and microbiological data were recorded in addition to monthly
weights during treatment.
Results: Overall, patients had a signiﬁcant change in weight over the course of treatment (p < 0.0001).
After 2 months of treatment, 31.9% of patients had gained at least 5% body weight; by the end of
treatment, 62.4% of patients had gained at least 5% weight. Patients who gained weight did so in a linear
fashion throughout treatment. Cavitary and extensive disease, a positive smear, and a positive culture
were predictors of weight gain (p < 0.05). No patients had relapses during the time period of the study.
Conclusions: Only a subset of patients treated for TB gain signiﬁcant weight. A greater burden of disease
was predictive of weight gain.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Tuberculosis (TB) remains a major health burden and a leading
cause of death worldwide.1 Malnutrition is a risk factor for the
development of TB.2 Malnutrition causes reduced proliferation of
T-cells and impaired cell-mediated immunity,3,4 which in turn
leads to increased susceptibility to infection.5 In the USA, adults
with low body mass index (BMI), little subcutaneous fat, or
reduced skeletal muscle mass have been shown to be at increased
risk of developing TB compared to those with a normal nutritional
status.6
Weight loss is also a major feature of TB. In a study of patients
with TB in Los Angeles County, 44.5% had weight loss and 40.6%
had anorexia.7 TB leads to a decrease in BMI,8–10 which results
from a loss of a combination of fat-free mass and fat mass.8,9,11 The
presence of moderate-to-severe malnutrition has been identiﬁed
as a risk factor for mortality during the ﬁrst 4 weeks of treatment
for TB.12* Corresponding author. Tel.: +1 713 798 7152.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Nutritional recovery and weight gain occur during treatment
for TB.9,10 However, it remains unclear whether weight gain can be
used as a marker of a treatment response. Kennedy et al. found that
neither a microbiological response nor relapse inﬂuenced weight
gain during treatment.10 However, another study found that a
change in weight over time is a predictor of the treatment
outcome, even after adjustment for confounders.13 Lack of a 5%
weight gain during the 2-month intensive phase of TB therapy in
patients who are underweight at diagnosis has also been shown to
be associated with an increased risk of relapse.14
The effect of TB therapy on weight may be confounded by
inadequate nutritional intake. For example, in Tanzania, patients
had improvement in weight during TB treatment, but these
improvements only persisted as long as the patients remained
hospitalized, likely due to better nutritional intake during
hospitalization.10 Increased understanding of how patients gain
weight during TB treatment in a non-resource poor country such as
the USA may provide an insight into the relationship between TB
and malnutrition. The purpose of this study was to determine
whether weight gain occurs during the course of TB treatment in
the USA and to determine whether patient or disease factors can
predict patterns of weight gain.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Demographics and baseline characteristics of patients with
active tuberculosis (N = 134)
Age, years, mean  SEM 48  1
Male, n (%) 93 (69.4)
Ethnicity, n (%)
Non-Hispanic
Hispanic
66 (49.3)
68 (50.7)
Race, n (%)
Caucasian
African-American
Asian
80 (59.7)
25 (18.7)
29 (21.6)
Smoking status, n (%)
Non-smoker
Current smoker
Former smoker
65 (48.5)
33 (24.6)
36 (26.9)
Alcohol use, n (%) 19 (14.2)
Co-morbidities, n (%)
Diabetes
Hepatitis Ba
Hepatitis Cb
Malignancy
51 (38.1)
5 (5.3)
16 (17.2)
14 (10.5)
SEM, standard error of the mean.
a Patients tested, n = 95.
b Patients tested, n = 93.
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2.1. Study population
This was a retrospective cohort study of patients treated for
active TB in the pulmonary clinic at Ben Taub General Hospital,
part of a community-owned healthcare system in Houston, Texas,
USA. The diagnosis was made by positive culture, detection of
Mycobacterium tuberculosis complex through PCR, or, for pleural
disease, clinical suspicion in combination with lymphocytic
pleural ﬂuid and improvement with treatment. All patients
received daily therapy for 14 days followed by daily or thrice-
weekly doses during the initiation phase. During the continuation
phase, all patients received either daily or thrice-weekly therapy
for a minimum of 4 months. Patients with both cavitary disease
and lack of sputum culture conversion were treated for 9 months.
Nine months of treatment was also given to patients with cavitary
disease, extensive disease, or lack of sputum culture conversion at
the discretion of the treating physician. Cavitary disease was
determined by the presence of cavities on plain chest radiograph.
Extensive disease was deﬁned as lesion(s) or inﬁltrates involving at
least one hemithorax. Culture conversion was deﬁned as negative
cultures within 2 months of treatment.
Patients who started treatment on or after January 1, 2010 and
completed treatment by December 31, 2014 were included.
Patients had to have a recorded weight at treatment initiation,
completion of treatment, and at least once in the intervening
months. Pregnant patients and patients with HIV co-infection were
excluded. Patients with HIV were excluded, because patients with
HIV and TB co-infection are cared for in a dedicated HIV clinic. The
study was approved by the Institutional Review Board at Baylor
College of Medicine, and a waiver of consent was obtained.
2.2. Data collection
The electronic medical records, as well as records from the City
of Houston Department of Health and Human Services, were
reviewed. Patient demographics, height, weight, medical history,
radiographic imaging, and microbiological data were collected. In
addition, the following information was recorded: history regard-
ing tobacco or alcohol abuse; comorbidities; treatment regimens
and duration; smear, culture, and sensitivity data; ﬁndings on
chest radiographs at the time of diagnosis; and relapse by
December 2014.
BMI was calculated from height and weight. Patients were
divided into three categories based on the World Health
Organization (WHO) classiﬁcation: BMI <18.5 kg/m2 was consid-
ered underweight, BMI 18.5 and <30 kg/m2 was considered
normal weight/overweight, and BMI 30 kg/m2 was considered
obese. The weight change was determined both by absolute change
in weight in kilograms as well as the percentage change in weight,
deﬁned as the change in weight divided by the weight at initiation
of treatment, expressed as a percentage.
2.3. Statistical analyses
Summary statistics are presented as the mean  standard error
of the mean. Bivariate associations were examined using the Student
t-test or Chi-square test, as appropriate. Comparisons of weights at
different time points were performed using repeated measures
analysis of variance (ANOVA) and post-hoc Tukey’s test. Categorical
variables were compared using the Chi-square test. Univariate
regression modeling was performed to determine the inﬂuence of
demographic and clinical variables on weight gain. Beta coefﬁcients
are presented with 95% conﬁdence intervals. All analyses were
performed using Stata 9.0 software (StataCorp LP, College Station, TX,USA). All p-values are two-sided, with p < 0.05 considered statisti-
cally signiﬁcant.
3. Results
One hundred thirty-four patients met the study inclusion
criteria. Their mean age was 48  1 years. Patient characteristics are
summarized in Table 1. The majority of patients were male, and
approximately half of the patients were of Hispanic ethnicity.
Comorbidities of the patients included diabetes mellitus, hepatitis
B virus infection, hepatitis C virus infection, and malignancy.
Signiﬁcant alcohol use was reported by 14.2% of patients, and
24.6% were current smokers.
Disease characteristics are summarized in Table 2. The majority
of patients had pulmonary disease. Ten of the patients with
extrapulmonary disease had tuberculous pleuritis. More than half
of the patients were treated for 9 months. Of the 123 patients with
pulmonary disease, 76.4% had positive sputum smears at the time
of diagnosis and 98.3% had positive sputum cultures. Of the
120 patients with pulmonary TB and a plain chest radiograph at the
time of diagnosis, 49.2% had cavitary disease and 30.8% had
extensive disease. Eighty-one patients with culture-positive
pulmonary TB had sputum conversion at 2 months.
Table 3 summarizes the changes in weight and BMI of the
patients during treatment. Overall, patients had a signiﬁcant
change in weight, deﬁned as at least 5% weight gain, over the
course of treatment (p < 0.001); however, this weight gain
occurred after 2 months of treatment. In the patients with weights
at all three time points, end-of-treatment weight was signiﬁcantly
increased from both the initial weight and weight at 2 months. BMI
increased signiﬁcantly after 2 months of treatment. At the end of
treatment, BMI was signiﬁcantly increased from initial BMI and
BMI at 2 months (overall p < 0.0001). The proportion of patients
who were underweight and overweight did not change signiﬁ-
cantly after treatment (p = 0.09).
As shown in Fig. 1, after 2 months of treatment, only 31.9% of
patients had gained 5% or more weight, but by the end of
treatment, 62.4% of patients had gained at least 5% body weight
(p < 0.001). In those patients who did gain 5% of weight by the end
of treatment, there was a linear increase in weight over the
treatment period (b = 1.67, R2 = 0.931, p < 0.001), whereas in
those patients who did not gain 5% of weight by the end of
Table 2
Characteristics of tuberculosis disease (N = 134)
Type of TB infection, n (%)
Pulmonary only
Extrapulmonary only
Both
104 (79.1)
11 (8.9)
19 (11.9)
Pleural disease, n (%) 10 (7.5)
Treatment duration
6 months
9 months
12 months
41 (32.5)
71 (56.4)
14 (11.1)
Resistance, n (%)a
INH
Rifampicin
MDR (INH + rifampicin)
11 (8.6)
5 (3.9)
5 (3.9)
Sputum smear positive, n (%)b 94 (76.4)
Sputum culture positive, n (%)b 121 (98.3)
Cavitary disease, n (%)c 59 (49.2)
Extensive disease, n (%)c 37 (30.8)
Sputum culture conversion at 2 months, n (%)d
Yes
No
Unknown
81 (66.9)
29 (24.0)
11 (9.1)
TB, tuberculosis, INH, isoniazid, MDR, multidrug-resistant.
a Out of 128 patients with positive cultures.
b Out of 123 patients with pulmonary TB.
c Out of 120 patients with pulmonary TB and plain chest radiograph at the time of
diagnosis.
d Out of 121 patients with culture-positive pulmonary tuberculosis.
Fig. 1. (A) Proportion of patients with  5% weight gain and (B) Trends of weight
gain over treatment period in patients who gained at least 5% body weight and
patients who gained.
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treatment (b = 0.09, R2 = 0.117, p = 0.45).
The results of univariate analyses of predictors of percentage
weight gain at the end of treatment are summarized in
Table 4. Signiﬁcant positive predictors of percentage weight gain
over the course of treatment included having a positive smear,
positive culture, cavitary disease, extensive disease, and a longer
duration of treatment. Signiﬁcant negative predictors of percent-
age weight gain over the course of treatment included having a
diagnosis of malignancy or co-infection with hepatitis B and/or C
virus. There was a trend towards age being a signiﬁcant negative
predictor of weight gain (p = 0.07), and patients over 60 years of
age gained less weight compared to patients younger than 60 years
(p = 0.04). In addition, there was also a trend towards multidrug-
resistant TB (MDR-TB) being associated with weight loss (p = 0.09).
Nine patients (6.7%) died during the course of treatment. The
cause of death was malignancy in ﬁve patients, fulminant hepatic
failure in one patient, and acute respiratory distress syndrome in
one patient. Two patients died at home of unknown causes. Of the
36 patients who had at least 2 years post-treatment follow-up by
the end of the study period, none had reported relapses.Table 3
Anthropometric characteristics at baseline, 2 months, and end of therapy in tuberculo
Baseline
(n = 134)
After 2 months of tr
Height, cm 165.9  1.0 - 
Weight, kg 63.9  1.4 65.1  1.7 
BMI, kg/m2 23.2  0.5 23.7  0.6b
BMI category, n (%)
< 18.5
18.5 and <30
30
13 (9.7)
109 (81.3)
12 (9.0)
13 (11.2)
89 (76.7)
14 (12.1)
Weight change, kg - 0.8  0.7 
Weight change, % - 1.4  1.2 
BMI, body mass index; ANOVA, analysis of variance.
a Values expressed as the mean  standard error of the mean.
b p < 0.05 compared with baseline using ANOVA and Tukey’s post-hoc test.
c p < 0.05 compared with after 2 months of treatment using ANOVA and Tukey’s po4. Discussion
The purpose of this study was to determine whether weight
gain occurs over the course of TB treatment in the USA and to
determine whether patient or disease factors could predict
patterns of weight gain. The majority of patients with TB were
found not to be underweight at the time of diagnosis, and only asis patientsa
eatment (n = 116) At end of treatment
(n = 125)
p-Value
-
68.7  1.4b,c <0.001
25.1  0.5b,c <0.001
4 (3.2)
106 (84.8)
15 (12.0)
0.15
5.1  0.5
8.7  0.8
st-hoc test.
Table 4
Univariate analysis of predictors of percentage weight gain at the end of treatment
Variable Coefﬁcient (b) 95% CI p-Value
Sex 2.7 0.2, 0.0 0.13
Age 0.1 0.2, 0.0 0.07
Age 60 years 4.2 8.1, 0.2 0.04
Positive smear 4.2 0.7, 7.9 0.02
Positive culture 8.0 0.4, 15.6 0.04
MDR-TB 7.1 15.3, 1.2 0.09
Cavitary disease 4.2 0.9, 7.4 0.01
Extensive disease 5.6 2.0, 9.1 0.002
9 vs. 6 months of treatment 4.6 1.2, 8.0 0.01
Underweight at diagnosis 7.7 2.3, 13.1 0.006
Malignancy 10.9 17.3, 4.4 0.001
Hepatitis B and/or C 4.8 10.0, 0.4 0.07
CI, conﬁdence interval; MDR-TB, multidrug-resistant tuberculosis.
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For those who gained weight, this weight increase occurred not
only during the intensive phase of therapy, but continued linearly
throughout the course of treatment. Evidence of a greater disease
burden, including positive microbiological tests, cavitary disease,
and extensive disease, were positive predictors of weight gain
during treatment.
At the time of diagnosis, only a small percentage of patients
were underweight (11.2%). The presence of malignancy and
uncontrolled diabetes may have contributed to the underweight
state of some patients. One underweight patient died; that
patient’s death was related to malignancy. Overall, being
underweight at baseline was actually a signiﬁcant positive
predictor of weight gain. Prior studies of weight gain and TB have
included more than 70% of patients who are underweight at
diagnosis.10,12 The exclusion of patients with HIV co-infection in
this study may have contributed to the low incidence of
underweight at baseline. HIV is strongly associated with under-
nutrition,15 and concomitant HIV co-infection leads to exacerba-
tion of TB-associated wasting.16 Prior studies of nutritional status
in TB patients have included a signiﬁcant proportion of HIV-
positive patients–36% in a study in Tanzania10 and 80% in a study in
Malawi.12 However, in another study from Peru, in which HIV
patients were excluded, only 21% of patients were underweight at
the time of diagnosis.17
It was found that 52.6% of patients at 2 months and 38.4% by the
end of treatment did not gain signiﬁcant weight. Of the patients
who gained weight, this weight gain occurred linearly over the
entire treatment period. Bernabe-Ortiz et al. similarly found that
some patients gained increasing weight over the treatment period,
while others initially lost weight.13 In another study of patients
with MDR-TB, some patients had consistent weight gain through-
out treatment.18 However, a prior study in Vietnam showed that
although patients gained weight throughout treatment, most
weight gain occurred during the ﬁrst 2 months.19
The mechanisms leading to weight loss in TB and subsequent
weight gain after treatment are not completely understood. Even
with increased calorie and macronutrient intake, infection with
TB leads to loss of fat-free and fat mass.20 In this study, patients
with a higher burden of disease, as evidenced by positive smears,
cavitary disease, and/or extensive disease, had a greater weight
gain over the course of treatment. This suggests that greater
disease burden leads to more malnutrition at the time of
diagnosis, which, in combination with adequate nutrition, can
be reversed. However, although the most dramatic reduction in
bacillary load occurs during the intensive phase of therapy, it may
take time to replenish fat and fat-free mass that has been lost. In
support of this, it was found that patients who gained weight did
so in a linear fashion throughout the course of treatment in the
present study.In this study, sex was found not to have a signiﬁcant effect on
weight gain during TB treatment. Sex may affect body composition
rather than weight. In a prior study, sex did not affect mean weight
gain during TB treatment, but male patients gained relatively more
fat-free mass whereas female patients gained relatively more fat
mass.21 In this study, there was also a trend towards a negative
association between MDR-TB and percentage weight gain.
However, the low number of patients with MDR-TB likely led to
the lack of signiﬁcance of this association. Prior studies have
demonstrated that a lack of weight gain in patients with MDR-TB is
associated with worse outcomes.18,22,23 Patients in these studies
had difﬁculty gaining weight, which may be secondary to the side
effects of second-line medications.
This study had several limitations. Because of its retrospective
nature, no information was available on dietary intake or body
composition. Therefore, the possibility that inadequate dietary
intake (due either to poor appetite or inadequate access to food)
limited weight gain in some patients cannot be excluded. Patients
with HIV were excluded from this study, which may affect the
generalizability of the results. However, only 6% of persons with TB
in the USA in 2014 were HIV-positive, and this number has
decreased over time.24 Finally, many of the patients received
9 months of treatment, and a longer duration of treatment was
associated with greater weight gain. Thus, it is possible that patient
weight gain is a function of time rather than duration of treatment.
In summary, in a cohort of patients being treated for TB in the
USA, a signiﬁcant proportion gained weight and did so linearly
throughout treatment. However, approximately one-third of
patients did not gain weight. A better understanding of why
certain patients with TB gain weight during treatment while others
do not may help us understand how to reverse the cachexia of
other chronic diseases.
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